Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Published Sep 23, 2016
58 pages — Published Sep 23, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Sosei Group Corporation (Sosei) is a biopharmaceutical company that develops and commercializes drugs. The companys products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive and SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. Soseis NVA237 is a long acting bronchodilator for the treatment of chronic obstructive pulmonary disease. The company provides treatment of Alzheimer's disease, schizophrenia, cancer, migraine, addiction, metabolic disease, and other indications. It operates through various pharmaceutical companies.

Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharmaceuticals & Healthcare eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which hav

  
Source:
Document ID
GDPH82131D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Sosei Group Corporation, Pharmaceuticals &Healthcare, Deals By Year, 2010 to YTD 201652
Sosei Group Corporation, Pharmaceuticals &Healthcare Deals By Type, 2010 to YTD 201671
Sosei Group Corporation, Pharmaceuticals &Healthcare, Deals By Region, 2010 to YTD 201681
Sosei Group Corporation, Pharmaceuticals &Healthcare, Deals By Therapy Area, 2010 to YTD 201692
Sosei Group Corporation, Medical Devices Deals, 2010 to YTD 2016111
Sosei Group Corporation, Pharmaceuticals &Healthcare, Deals Summary, 2010 to YTD 2016122
Sosei Group Corporation, Pharmaceuticals &Healthcare, Deal Details1440
  Venture Financing141
    Heptares Therapeutics Raises US$21 Million In Series B Financing142
  Partnerships161
    Heptares Therapeutics and leadXpro Enter into Agreement161
    Heptares Therapeutics to Form Partnership with Kymab171
    Heptares Therapeutics Enters into Agreement with Pfizer181
    Sosei Plans to Enter into Agreement with Novartis191
    Sosei Enters Into Distribution Agreement With Fujifilm Pharma For SO-1105201
    MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs212
    Heptares Enters Into Research Agreement With Cubist Pharma For New Medicines Targeting GPCRs231
    ZoBio Enters Into Drug Discovery Agreement With Heptares Therapeutics For Fragment Ligands241
    Activus Pharma Enters Into Co-Development Agreement With CEOLIA Pharma251
    Activus Pharma Enters Into An Agreement With Gifu Pharma University261
    AstraZeneca Enters Into Co-Development Agreement With Heptares272
    Sosei Enters Into Co-Development Agreement With Toa Pharma291
    Heptares Therapeutics Enters Into Drug Discovery Collaboration With Takeda Pharma302
  Licensing Agreements321
    Allergan Enters into Licensing Agreement with Heptares Therapeutics322
    Teva Pharma Enters into Licensing Agreement with Heptares Therapeutics341
    AstraZeneca to Enter into Licensing Agreement with Heptares Therapeutics for HTL-1071352
    Shire Exercises Option To License Adenosine A2A From Heptares Therapeutics372
    BioAlliance Pharma Extends Licensing Agreement With Sosei For Loramyc391
  Equity Offering401
    Sosei Group Raises USD33 Million in Private Placement of Shares402
    Sosei Group to Raise USD7 Million in Private Placement of Shares422
    Sosei Group to Raise USD66 Million in Public Offering of Shares442
    Jitsubo to Raise USD1.7 Million in Private Placement461
    Sosei Announces Private Placement Of Preference Shares For US$3.9 Million472
  Asset Transactions491
    Beijing Tide Pharma Acquires Rights To SD118 From Sosei491
  Acquisition501
    Sosei Acquires Heptares Therapeutics for USD400 Million502
    Sosei to Acquire Stake in Jitsubo for USDUSD1.8 Million521
    Sosei Group Acquires Activus Pharma531
Sosei Group Corporation - Key Competitors541
Key Employees551
Locations And Subsidiaries562
  Head Office561
  Other Locations &Subsidiaries562
Appendix581
  Methodology581
  About GlobalData581
  Contact Us581
  Disclaimer581

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile" Sep 23, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sosei-Group-Corporation-4565-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6932>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Sosei Group Corporation (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Sep 23, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Sosei-Group-Corporation-4565-Pharmaceuticals-Healthcare-Deals-and-Alliances-Profile-2148-6932>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research